PCE

ASCO 2022: What’s New in Mantle Cell Lymphoma

Episode Summary

In this podcast episode, listen to Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, discuss key data for mantle cell lymphoma presented at the 2022 ASCO annual meeting, including data on BTK inhibitors, CAR T-cell therapy, and other novel agents targeting ROR1.

Episode Notes

In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:

• Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCL
• Updated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCL
• Results from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLL
• Preliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapies

Presenters:

Tycel J. Phillips, MD 
Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow Transplantation
Associate Professor of Medicine
University of Michigan 
Rogel Cancer Center 
Ann Arbor, Michigan

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate, Department of Medicine
Johns Hopkins University
Nurse Practitioner, Department of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Content supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Link to full program, including a downloadable highlights slideset:
https://bit.ly/3yufCU4